Axsome Therapeutics (AXSM) Assets (2015 - 2026)

Axsome Therapeutics' Assets history runs 12 years deep, the most recent figure standing at $713.6 million for Q1 2026.

• In Q1 2026, Assets rose 19.6% year-over-year to $713.6 million; the TTM figure through Mar 2026 stood at $713.6 million (up 19.6% YoY), while the FY2025 annual figure was $689.8 million, up 21.34% from the prior year.
• Assets came in at $713.6 million for Q1 2026 at Axsome Therapeutics, up from $689.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $713.6 million in Q1 2026 to a low of $88.6 million in Q1 2022.
• A 5-year average of $509.6 million and a median of $568.5 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets sank 46.94% in 2022 and soared 339.45% in 2023, its largest moves.
• Axsome Therapeutics' Assets stood at $331.5 million in 2022, then soared by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024, then gained by 21.34% to $689.8 million in 2025, then advanced by 3.45% to $713.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $713.6 million, $689.8 million, and $669.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison